APO Research
Talk to an analyst

APO RESEARCH · REPORT

Flu Prevention

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Flu Prevention Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchFlu Prevention Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Flu Prevention Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Flu Prevention Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Flu Prevention Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Flu Prevention Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Flu Prevention market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Flu Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Flu Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Flu Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Flu Prevention market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Flu Prevention market include AstraZeneca, BCHT, CSL, KM Biologics, Sinovac, GSK, Hualan Bio, Viatris and Jiangsu GDK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Flu Prevention market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Flu Prevention and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Flu Prevention sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Flu Prevention market size, projected growth trends, production technologies, key applications, and end-use industries.

Flu Prevention Segment by Company

AstraZeneca

BCHT

CSL

KM Biologics

Sinovac

GSK

Hualan Bio

Viatris

Jiangsu GDK

Sanofi

Changchun Institute of Biological

Flu Prevention Segment by Type

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Flu Prevention Segment by Application

6 Months to 3 Years

> 3 Years

Flu Prevention Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Flu Prevention status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Flu Prevention market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Flu Prevention significant trends, drivers, influence factors in global and regions.

6. To analyze Flu Prevention competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Flu Prevention market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Flu Prevention and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Flu Prevention.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Flu Prevention market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Flu Prevention industry.

Chapter 3: Detailed analysis of Flu Prevention manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Flu Prevention in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Flu Prevention in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Flu Prevention Industry Trends Table 2. Flu Prevention Industry Drivers Table 3. Flu Prevention Industry Opportunities and Challenges Table 4. Flu Prevention Industry Restraints Table 5. Global Flu Prevention Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Flu Prevention Revenue Share by Company (2021-2026) Table 7. Global Flu Prevention Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Flu Prevention Sales Volume Share by Company (2021-2026) Table 9. Global Flu Prevention Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Flu Prevention Company Ranking, (2024-2026) & (USD Million) Table 11. Global Flu Prevention Key Company Manufacturing Base & Headquarters Table 12. Global Flu Prevention Company, Product Type & Application Table 13. Global Flu Prevention Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Flu Prevention by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Trivalent Influenza Vaccine Table 18. Significant Companies of Quadrivalent Influenza Vaccine Table 19. Global Flu Prevention Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Flu Prevention Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Flu Prevention Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Flu Prevention Sales Volume Share by Type (2021-2026) Table 23. Global Flu Prevention Sales Volume Share by Type (2027-2032) Table 24. Global Flu Prevention Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Flu Prevention Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Flu Prevention Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Flu Prevention Sales Value Share by Type (2021-2026) Table 28. Global Flu Prevention Sales Value Share by Type (2027-2032) Table 29. Significant Companies of 6 Months to 3 Years Table 30. Significant Companies of > 3 Years Table 31. Global Flu Prevention Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Flu Prevention Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Flu Prevention Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Flu Prevention Sales Volume Share by Application (2021-2026) Table 35. Global Flu Prevention Sales Volume Share by Application (2027-2032) Table 36. Global Flu Prevention Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Flu Prevention Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Flu Prevention Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Flu Prevention Sales Value Share by Application (2021-2026) Table 40. Global Flu Prevention Sales Value Share by Application (2027-2032) Table 41. Global Flu Prevention Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Flu Prevention Sales by Region (2021-2026) & (M Doses) Table 43. Global Flu Prevention Sales Market Share by Region (2021-2026) Table 44. Global Flu Prevention Sales by Region (2027-2032) & (M Doses) Table 45. Global Flu Prevention Sales Market Share by Region (2027-2032) Table 46. Global Flu Prevention Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Flu Prevention Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Flu Prevention Sales Value Share by Region (2021-2026) Table 49. Global Flu Prevention Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Flu Prevention Sales Value Share by Region (2027-2032) Table 51. Global Flu Prevention Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Flu Prevention Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Flu Prevention Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Flu Prevention Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Flu Prevention Sales by Country (2021-2026) & (M Doses) Table 56. Global Flu Prevention Sales Market Share by Country (2021-2026) Table 57. Global Flu Prevention Sales by Country (2027-2032) & (M Doses) Table 58. Global Flu Prevention Sales Market Share by Country (2027-2032) Table 59. Global Flu Prevention Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Flu Prevention Sales Value Market Share by Country (2021-2026) Table 61. Global Flu Prevention Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Flu Prevention Sales Value Market Share by Country (2027-2032) Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AstraZeneca Flu Prevention Product Portfolio Table 67. AstraZeneca Recent Development Table 68. BCHT Company Information Table 69. BCHT Business Overview Table 70. BCHT Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. BCHT Flu Prevention Product Portfolio Table 72. BCHT Recent Development Table 73. CSL Company Information Table 74. CSL Business Overview Table 75. CSL Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CSL Flu Prevention Product Portfolio Table 77. CSL Recent Development Table 78. KM Biologics Company Information Table 79. KM Biologics Business Overview Table 80. KM Biologics Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. KM Biologics Flu Prevention Product Portfolio Table 82. KM Biologics Recent Development Table 83. Sinovac Company Information Table 84. Sinovac Business Overview Table 85. Sinovac Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sinovac Flu Prevention Product Portfolio Table 87. Sinovac Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GSK Flu Prevention Product Portfolio Table 92. GSK Recent Development Table 93. Hualan Bio Company Information Table 94. Hualan Bio Business Overview Table 95. Hualan Bio Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hualan Bio Flu Prevention Product Portfolio Table 97. Hualan Bio Recent Development Table 98. Viatris Company Information Table 99. Viatris Business Overview Table 100. Viatris Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Viatris Flu Prevention Product Portfolio Table 102. Viatris Recent Development Table 103. Jiangsu GDK Company Information Table 104. Jiangsu GDK Business Overview Table 105. Jiangsu GDK Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Jiangsu GDK Flu Prevention Product Portfolio Table 107. Jiangsu GDK Recent Development Table 108. Sanofi Company Information Table 109. Sanofi Business Overview Table 110. Sanofi Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sanofi Flu Prevention Product Portfolio Table 112. Sanofi Recent Development Table 113. Changchun Institute of Biological Company Information Table 114. Changchun Institute of Biological Business Overview Table 115. Changchun Institute of Biological Flu Prevention Sales (M Doses), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Changchun Institute of Biological Flu Prevention Product Portfolio Table 117. Changchun Institute of Biological Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Flu Prevention Distributors List Table 121. Flu Prevention Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Flu Prevention Product Image Figure 2. Global Flu Prevention Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 4. Global Flu Prevention Sales (2021-2032) & (M Doses) Figure 5. Global Flu Prevention Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Flu Prevention Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Trivalent Influenza Vaccine Image Figure 10. Quadrivalent Influenza Vaccine Image Figure 11. Global Flu Prevention Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Flu Prevention Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Flu Prevention Sales Volume Share by Type (2021-2032) Figure 14. Global Flu Prevention Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Flu Prevention Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Flu Prevention Sales Value Share by Type (2021-2032) Figure 17. 6 Months to 3 Years Image Figure 18. > 3 Years Image Figure 19. Global Flu Prevention Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Flu Prevention Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Flu Prevention Sales Volume Share by Application (2021-2032) Figure 22. Global Flu Prevention Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Flu Prevention Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Flu Prevention Sales Value Share by Application (2021-2032) Figure 25. Global Flu Prevention Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Flu Prevention Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Flu Prevention Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Flu Prevention Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 30. North America Flu Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Flu Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Flu Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 36. South America Flu Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Flu Prevention Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Flu Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Flu Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Flu Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Flu Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Flu Prevention Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Flu Prevention Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Applications
  • 6 Months to 3 Years
  • > 3 Years
Companies covered
  • AstraZeneca
  • BCHT
  • CSL
  • KM Biologics
  • Sinovac
  • GSK
  • Hualan Bio
  • Viatris
  • Jiangsu GDK
  • Sanofi
  • Changchun Institute of Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Flu Prevention Sales Value (2021-2032)
  4. 1.2.2 Global Flu Prevention Sales Volume (2021-2032)
  5. 1.2.3 Global Flu Prevention Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Flu Prevention Market Dynamics
  1. 2.1 Flu Prevention Industry Trends
  2. 2.2 Flu Prevention Industry Drivers
  3. 2.3 Flu Prevention Industry Opportunities and Challenges
  4. 2.4 Flu Prevention Industry Restraints
3 Flu Prevention Market by Company
  1. 3.1 Global Flu Prevention Company Revenue Ranking in 2025
  2. 3.2 Global Flu Prevention Revenue by Company (2021-2026)
  3. 3.3 Global Flu Prevention Sales Volume by Company (2021-2026)
  4. 3.4 Global Flu Prevention Average Price by Company (2021-2026)
  5. 3.5 Global Flu Prevention Company Ranking (2024-2026)
  6. 3.6 Global Flu Prevention Company Manufacturing Base and Headquarters
  7. 3.7 Global Flu Prevention Company Product Type and Application
  8. 3.8 Global Flu Prevention Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Flu Prevention Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Flu Prevention Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Flu Prevention Market by Type
  1. 4.1 Flu Prevention Type Introduction
  2. 4.1.1 Trivalent Influenza Vaccine
  3. 4.1.2 Quadrivalent Influenza Vaccine
  4. 4.2 Global Flu Prevention Sales Volume by Type
  5. 4.2.1 Global Flu Prevention Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Flu Prevention Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Flu Prevention Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Flu Prevention Sales Value by Type
  9. 4.3.1 Global Flu Prevention Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Flu Prevention Sales Value by Type (2021-2032)
  11. 4.3.3 Global Flu Prevention Sales Value Share by Type (2021-2032)
5 Flu Prevention Market by Application
  1. 5.1 Flu Prevention Application Introduction
  2. 5.1.1 6 Months to 3 Years
  3. 5.1.2 > 3 Years
  4. 5.2 Global Flu Prevention Sales Volume by Application
  5. 5.2.1 Global Flu Prevention Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Flu Prevention Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Flu Prevention Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Flu Prevention Sales Value by Application
  9. 5.3.1 Global Flu Prevention Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Flu Prevention Sales Value by Application (2021-2032)
  11. 5.3.3 Global Flu Prevention Sales Value Share by Application (2021-2032)
6 Flu Prevention Regional Sales and Value Analysis
  1. 6.1 Global Flu Prevention Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Flu Prevention Sales by Region (2021-2032)
  3. 6.2.1 Global Flu Prevention Sales by Region: 2021-2026
  4. 6.2.2 Global Flu Prevention Sales by Region (2027-2032)
  5. 6.3 Global Flu Prevention Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Flu Prevention Sales Value by Region (2021-2032)
  7. 6.4.1 Global Flu Prevention Sales Value by Region: 2021-2026
  8. 6.4.2 Global Flu Prevention Sales Value by Region (2027-2032)
  9. 6.5 Global Flu Prevention Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Flu Prevention Sales Value (2021-2032)
  12. 6.6.2 North America Flu Prevention Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Flu Prevention Sales Value (2021-2032)
  15. 6.7.2 Europe Flu Prevention Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Flu Prevention Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Flu Prevention Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Flu Prevention Sales Value (2021-2032)
  21. 6.9.2 South America Flu Prevention Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Flu Prevention Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Flu Prevention Sales Value Share by Country, 2025 VS 2032
7 Flu Prevention Country-level Sales and Value Analysis
  1. 7.1 Global Flu Prevention Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Flu Prevention Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Flu Prevention Sales by Country (2021-2032)
  4. 7.3.1 Global Flu Prevention Sales by Country (2021-2026)
  5. 7.3.2 Global Flu Prevention Sales by Country (2027-2032)
  6. 7.4 Global Flu Prevention Sales Value by Country (2021-2032)
  7. 7.4.1 Global Flu Prevention Sales Value by Country (2021-2026)
  8. 7.4.2 Global Flu Prevention Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Flu Prevention Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Flu Prevention Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Flu Prevention Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Flu Prevention Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Flu Prevention Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Flu Prevention Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Flu Prevention Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Flu Prevention Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Flu Prevention Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Flu Prevention Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Flu Prevention Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Flu Prevention Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Flu Prevention Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Flu Prevention Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Flu Prevention Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Flu Prevention Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Flu Prevention Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Flu Prevention Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Flu Prevention Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Flu Prevention Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Flu Prevention Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Flu Prevention Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Flu Prevention Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Flu Prevention Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Flu Prevention Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Flu Prevention Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Flu Prevention Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Flu Prevention Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Flu Prevention Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Flu Prevention Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Flu Prevention Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Flu Prevention Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Flu Prevention Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Flu Prevention Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Flu Prevention Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Flu Prevention Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Flu Prevention Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Flu Prevention Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Flu Prevention Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Flu Prevention Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Flu Prevention Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Flu Prevention Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Flu Prevention Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Flu Prevention Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Flu Prevention Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Flu Prevention Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Flu Prevention Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Flu Prevention Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Flu Prevention Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Flu Prevention Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Flu Prevention Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Flu Prevention Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Flu Prevention Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Flu Prevention Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Flu Prevention Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Flu Prevention Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Flu Prevention Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Flu Prevention Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Flu Prevention Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Flu Prevention Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Flu Prevention Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Flu Prevention Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Flu Prevention Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Flu Prevention Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Flu Prevention Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Flu Prevention Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Flu Prevention Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Flu Prevention Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Flu Prevention Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Flu Prevention Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Flu Prevention Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Flu Prevention Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Flu Prevention Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Flu Prevention Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Flu Prevention Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Flu Prevention Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Flu Prevention Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Flu Prevention Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Flu Prevention Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Flu Prevention Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Flu Prevention Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Flu Prevention Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Flu Prevention Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Flu Prevention Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Flu Prevention Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Flu Prevention Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 BCHT
  8. 8.2.1 BCHT Company Information
  9. 8.2.2 BCHT Business Overview
  10. 8.2.3 BCHT Flu Prevention Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BCHT Flu Prevention Product Portfolio
  12. 8.2.5 BCHT Recent Developments
  13. 8.3 CSL
  14. 8.3.1 CSL Company Information
  15. 8.3.2 CSL Business Overview
  16. 8.3.3 CSL Flu Prevention Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSL Flu Prevention Product Portfolio
  18. 8.3.5 CSL Recent Developments
  19. 8.4 KM Biologics
  20. 8.4.1 KM Biologics Company Information
  21. 8.4.2 KM Biologics Business Overview
  22. 8.4.3 KM Biologics Flu Prevention Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 KM Biologics Flu Prevention Product Portfolio
  24. 8.4.5 KM Biologics Recent Developments
  25. 8.5 Sinovac
  26. 8.5.1 Sinovac Company Information
  27. 8.5.2 Sinovac Business Overview
  28. 8.5.3 Sinovac Flu Prevention Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Flu Prevention Product Portfolio
  30. 8.5.5 Sinovac Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Flu Prevention Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GSK Flu Prevention Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Hualan Bio
  38. 8.7.1 Hualan Bio Company Information
  39. 8.7.2 Hualan Bio Business Overview
  40. 8.7.3 Hualan Bio Flu Prevention Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Bio Flu Prevention Product Portfolio
  42. 8.7.5 Hualan Bio Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Flu Prevention Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Flu Prevention Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Jiangsu GDK
  50. 8.9.1 Jiangsu GDK Company Information
  51. 8.9.2 Jiangsu GDK Business Overview
  52. 8.9.3 Jiangsu GDK Flu Prevention Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu GDK Flu Prevention Product Portfolio
  54. 8.9.5 Jiangsu GDK Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Flu Prevention Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Flu Prevention Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Changchun Institute of Biological
  62. 8.11.1 Changchun Institute of Biological Company Information
  63. 8.11.2 Changchun Institute of Biological Business Overview
  64. 8.11.3 Changchun Institute of Biological Flu Prevention Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Changchun Institute of Biological Flu Prevention Product Portfolio
  66. 8.11.5 Changchun Institute of Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Flu Prevention Value Chain Analysis
  2. 9.1.1 Flu Prevention Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Flu Prevention Sales Mode & Process
  6. 9.2 Flu Prevention Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Flu Prevention Distributors
  9. 9.2.3 Flu Prevention Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst